Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00026897
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2001-11-14
Brief Title:
Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer
Sponsor:
National Cancer Institute NCI
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Trafficking of Indium-111-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer
Status:
COMPLETED
Status Verified Date:
2002-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients undergoing immunotherapy for advanced cancer under IRB-approved protocols who are to receive immune cells in adoptive transfer will have less than or equal to 50 of those cells labeled with In-111-oxine and administered along with the remainder of their unlabeled cells They will then undergo gamma-camera imaging over the next 0-7 days and blood samples and tumor sites which are accessible with minimal surgery low-risk biopsy may be sampled in some patients for enumeration of radiolabeled cells End-points will be tumor and normal organ imaging and the amount of In-111 per gram of tissue in biopsies or per ml of blood
Detailed Description:
Patients undergoing immunotherapy for advanced cancer under IRB-approved protocols who are to receive immune cells in adoptive transfer will have less than or equal to 50 of those cells labeled with In-111-oxine and administered along with the remainder of their unlabeled cells They will then undergo gamma-camera imaging over the next 0-7 days and blood samples and tumor sites which are accessible with minimal surgery low-risk biopsy may be sampled in some patients for enumeration of radiolabeled cells End-points will be tumor and normal organ imaging and the amount of In-111 per gram of tissue in biopsies or per ml of blood
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 98-C-0033 | None | None | None |